No abstract available.
Epidermal Cyst* ; Herpes Zoster*

No abstract available.
Knee* ; Nevus* ; Organoids*

Proliferating trichilemmal tumor (PTT) is an uncommon neoplasm originated from the outer root sheath of a hair follicle. Malignant transformation occurs occasionally in proliferating trichilemmal tumors, which can be manifested by sudden rapid growths. Histologically, the malignant proliferating trichilemmal tumors (MPTTs) have shown severe nuclear atypia, marked cellular pleomorphism with atypical mitoses, dyskeratotic cells and infiltrating margins. Squamous cell carcinoma (SCC) should be differentiated with MPTT which indicates characteristic trichilemmal keratinization. Large tumor is considered as a risk factor of metastasis in SCC, but the relationship between tumor size and metastasis in the MPTT is not yet clarified. In this report, two patients have large erythematous nodules with focal ulceration and necrosis on their scalps and were diagnosed as MPTT. Despite the large sizes of the tumors, there were no evidences of metastases. Herein, we report 2 cases of the large MPTT which are presented without metastasis.
Carcinoma, Squamous Cell ; Hair Follicle ; Humans ; Mitosis ; Necrosis ; Neoplasm Metastasis* ; Risk Factors ; Scalp* ; Ulcer

No abstract available.
Dermatitis, Allergic Contact

No abstract available.
Angiofibroma ; Carbon ; Carbon Dioxide ; Lasers, Gas

No abstract available.
Adult ; Humans

BACKGROUND: Acquired bilateral nevus of Ota-like macules (ABNOM) is a dermal pigmented lesion common in individuals of Oriental origin. The Q-switched Nd:YAG laser (QSNYL) has been used successfully to treat a variety of benign, dermal, pigmented lesions, including nevus of Ota lesions. The similarity between ABNOM and nevus of Ota suggested that QSNYL may also be effective in the former. OBJECTIVE: To determine the efficacy and side-effect profiles of QSNYL treatment of ABNOM in Korean patients. METHODS: Of 42 Korean patients with ABNOM, 29 were treated with QSNYL (1,064 nm, 3 mm spot size, fluence 8~9.5 J/cm2), for up to 10 sessions each. Clinical photographs were taken before and after treatment. Lesion clearance was graded and complications such as hyperpigmentation, scarring, hypopigmentation, and erythema were assessed. RESULTS: Of the 29 treated patients, 19 (66%) showed excellent or good results. Of the patients who were treated more than 3 times, 76% showed good to excellent results. Two patients experienced post-laser hyperpigmentation (PLH), which persisted for more than one month, but no patient experienced persistent erythema or hypertrophic scarring. CONCLUSION: QSNYL is safe and effective in the treatment of ABNOM in Korean patients. Short-interval repetitive treatment is especially useful in improving therapeutic results and reducing PLH.
Cicatrix ; Cicatrix, Hypertrophic ; Erythema ; Humans ; Hyperpigmentation ; Hypopigmentation ; Laser Therapy ; Nevus ; Nevus of Ota

Trichodiscoma are hamartomas of the dermal portion of the hair disc, and these are found as asymptomatic flesh- colored papules 1~3 mm in diameter, and they are usually located on the face, trunk and thigh. Histopathologically, this is characterized by non-encapsulated fibrovascular lesion with a myxoid stroma surrounded by folliculo- sebaceous units. Birt-Hogg-Dube syndrome, which develops multiple trichodiscomas with fibrofolliculomas and skin tags, has been described. The case of solitary trichodischoma is rare. We recently encountered a 29-year-old woman with a solitary, dome-shaped papule on the right thigh. After histopathologic examination, the lesion was diagnosed as trichodiscoma.
Adult ; Birt-Hogg-Dube Syndrome ; Female ; Hair ; Hamartoma ; Humans ; Skin ; Thigh

Although injectable soft-tissue augmentation materials are extremely well-tolerated, undesirable effects sometimes occur. Whereas minor adverse events such as erythema, edema or bruising are generally reversible, the formation of foreign body granuloma, atypical mycobacterial infections or tissue necrosis may cause serious irreversible damages and disfigurement. We present here the case of a 50-year-old woman with an indurated painful nodule and patch on the right cheek, and this occurred after an unlicensed nonspecialist injected filler of unknown ingredients. The histopathologic findings showed granulomatous inflammation composed of lymphocytes, histiocytes and multinucleated giant cells with a Swiss cheese appearance. Although any acid-fast bacilli were not observed on Ziehl-Neelsen staining, the mycobacterial culture demonstrated an ivory-colored wet colony that was identified as M. chelonae by polymerase chain reaction-restriction fragment length polymorphism. The patient was treated with 1 g of clarithromycin for seven weeks, and the lesion improved considerably.
Cheek ; Cheese ; Clarithromycin ; Edema ; Erythema ; Female ; Foreign Bodies ; Giant Cells ; Granuloma, Foreign-Body ; Histiocytes ; Humans ; Inflammation ; Lymphocytes ; Middle Aged ; Mycobacterium ; Mycobacterium chelonae ; Necrosis

BACKGROUND: Epidermal growth factor receptor (EGFR) inhibitors are associated with cutaneous adverse events, including papulopustular eruption, xerosis, paronychia, hair abnormality and mucositis. In particular, acneiform eruptions might serve as the visible markers of anti-tumor activity and the therapeutic efficacy of EGFR inhibitors. OBJECTIVE: Our aims are to investigate the common cutaneous adverse events induced by cetuximab, which is one of the EGFR inhibitors approved by the US Food and Drug Administration, and to analyze whether the presence and severity of papulopustular eruptions have a correlation with the tumor response. METHODS: We retrospectively reviewed the medical records and clinical photographs of 114 Korean patients who had been treated with cetuximab at Asan Medical Center from September 2004 to March 2007. Results: Papulopustular eruptions occurred in 100 patients (87.7%) and this usually happened 10 days after starting chemotherapy. There was a tendency that the better the tumor responded to the chemotherapeutic agents including cetuximab, the more severe were the papulopustular eruptions. The papulopustular eruptions prominently improved after the treatment with topical agents such as benzoyl peroxide, metronidazole, clindamycin and retinoid, and with systemic agents such as minocycline and tetracycline, and there was no adverse event induced by this treatment for papulopustular eruptions. Xerosis appeared in 67 patients (58.8%), and there was a tendency that the more severe papulopustular eruptions were, the more frequently xerosis occurred. Paronychia occurred in 8 patients (7.0%). CONCLUSION: Although the cutaneous adverse events are burdensome to the patients, they might serve as visible markers of the anti-tumor activity and therapeutic efficacy of cetuximab and they can be easily and safely controlled with many topical and systemic agents. Therefore, it is important for dermatologists to properly treat these cutaneous adverse events and to reassure the patient to continue with the cetuximab treatment.
Acneiform Eruptions ; Antibodies, Monoclonal, Humanized ; Benzoyl Peroxide ; Clindamycin ; Drug Therapy, Combination ; Hair ; Humans ; Medical Records ; Metronidazole ; Minocycline ; Mucositis ; Paronychia ; Receptor, Epidermal Growth Factor ; Retrospective Studies ; Tetracycline ; United States Food and Drug Administration ; Cetuximab